Taken together, these data suggest that Notch may provide a critical compensatory signaling pathway through which HER2+ dormant tumor cells survive after therapy, and that this pathway can be effectively targeted pharmacologically in the neoadjuvant setting with Notch inhibitors in combination with HER2/neu-targeted therapies to prevent BC recurrence [93]. This evidence concerns the gene ERBB2 and breast cancer.